Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.
STAMFORD, Conn., Feb. 11, 2025 /PRNewswire/ — Neuvotion, Inc. is an early-stage medical device company developing AI-driven neuromodulation technologies and products for use in the neurorehabilitation, brain-computer interface (BCI), and physical therapy markets. Neuvotion has received FDA 510(k) clearance for their first product, NeuStim™, a non-invasive, surgery-free wearable that electrically stimulates muscles dynamically and with high-precision.
BOSTON, Feb. 11, 2025 /PRNewswire/ — InnoVoyce, a leading medical technology company, proudly announces its ISO 13485:2016 certification, underscoring its dedication to excellence in the design, manufacturing, installation, and servicing of lasers and fiber devices. Alongside this milestone, the company is thrilled to share that its FDA-cleared VYLO™ 455nm Blue Light Laser System is now available nationwide, offering healthcare professionals an advanced tool for treating laryngeal disorders and a wide range of surgical applications.
CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January for information on marketing and reimbursement practices.
Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has the potential to transform medical management of a common, but commonly overlooked, cause of high blood pressure.
A deep neural network called CHAIS may soon replace invasive procedures like catheterization as the new gold standard for monitoring heart health.
Newronika announced today that it received FDA investigational device exemption (IDE) for its deep brain stimulation (DBS) system.
A collaborative research team from POSTECH has successfully developed a gastric cancer model using 3D bioprinting technology and patient-derived cancer tissue fragments. This innovative model preserves the characteristics of actual patient tissues and is expected to rapidly evaluate and predict individual patient drug responses. The research has been published in the journal Advanced Science.
Senseonics (NYSE:SENS) announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.
CHICAGO, Feb. 6, 2025 /PRNewswire/ — Sibel Health, an award-winning medical technology company that develops advanced wearable sensors, software, and AI/ML algorithms for clinical trials and clinical care, is pleased to announce a major peer-reviewed publication, “Artificial Intelligence-Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis,” in JAMA Dermatology. This research describes a groundbreaking digital health technology designed to measure and reduce nighttime scratching in people with mild atopic dermatitis.